Delcath Systems Inc Reports Q2 2024 Financial Results
Intellectia.AI2024-08-06
Delcath Systems, Inc. Reports Q2 2024 Financial Results
Delcath Systems, Inc. (NASDAQ: DCTH) has reported its financial results for the second quarter ended June 30, 2024.
Key Financial Metrics
| Metric | Q2 2024 | Q1 2024 | Q2 2023 | YoY Change | QoQ Change | Consensus Estimate |
|---|---|---|---|---|---|---|
| Total Revenue | $7.8 million | Not Provided | $0.5 million | +1460% | - | $5.23 million |
| Earnings Per Share (EPS) | Not Provided | Not Provided | Not Provided | - | - | -$0.36 |
Delcath Systems, Inc. reported $7.8 million in total revenue for Q2 2024, a significant increase of 1460% year-over-year compared to $0.5 million in Q2 2023. Revenue exceeded the consensus estimate of $5.23 million.
Segment Revenue Performance
| Segment | Q2 2024 | Previous Guidance | YoY Change |
|---|---|---|---|
| HEPZATO KIT Sales (U.S.) | $6.6 million | Not Provided | - |
| CHEMOSAT Sales (Europe) | $1.2 million | Not Provided | - |
HEPZATO KIT sales in the U.S. contributed $6.6 million, while CHEMOSAT sales in Europe amounted to $1.2 million.
Key Operational Data
| Operational Metric | Q2 2024 |
|---|---|
| Cash and Investments | $19.9 million |
| Number of Active Treating Centers for HEPZATO KIT | 8 (as of end of Q2) |
Management Comments
CEO Gerard Michel expressed enthusiasm about the adoption of the HEPZATO KIT, stating, "We are excited about the continued adoption of the HEPZATO KIT and the positive feedback from physicians. We are optimistic that HEPZATO KIT will become a key part of the therapeutic approach for metastatic uveal melanoma patients."
Dividends or Share Repurchase Program
No information on any announced dividends or share repurchase programs was provided.
Forward Guidance
There was no specific forward guidance provided in the earnings report.
Stock Price Movement
Following the earnings release, Delcath Systems, Inc. saw a 2.46% increase in its stock price.
Delcath Systems continues to focus on the commercialization and adoption of its HEPZATO KIT, alongside expanding its presence in treating primary and metastatic liver cancers.
For more details, visit the company's investor relations page: Delcath Investor Relations
Note : Participation in the conference call scheduled at 4:30 pm Eastern Time is encouraged for additional insights into the company’s performance.
Genasys Inc Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Toll Brothers Reports Fourth Quarter and Full Year 2024 Financial Results
OilDri Corporation of America Reports Record First Quarter Fiscal 2025 Results
Share